This company has been marked as potentially delisted and may not be actively trading. Adagio Therapeutics (ADGI) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ADGI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Adagio Therapeutics GAAP EPS of -$0.36 beats by $0.15November 9, 2023 | msn.comOur Favorite Advent CalendarsOctober 10, 2023 | nytimes.comAdagio Therapeutics GAAP EPS of -$0.46 misses by $0.11August 11, 2023 | msn.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the FirmApril 3, 2023 | benzinga.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the FirmMarch 30, 2023 | markets.businessinsider.comFILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Invivyd, Inc. – IVVD, ADGIMarch 3, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGIFebruary 8, 2023 | benzinga.comForm 8.3 - Horizon Therapeutics PlcJanuary 25, 2023 | finance.yahoo.comInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopDecember 19, 2022 | benzinga.comAdagio Therapeutics, now Invivyd, retools its strategy after losing two executivesOctober 17, 2022 | bizjournals.comAdagio Therapeutics, Inc.: Adagio Therapeutics Announces Corporate Name Change to InvivydSeptember 15, 2022 | finanznachrichten.deInvivyd Announces Multiple Next Generation COVID-19 AntibodySeptember 12, 2022 | tmcnet.comInvivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsSeptember 12, 2022 | finance.yahoo.comShort Interest in Adagio Therapeutics, Inc. (NASDAQ:ADGI) Drops By 13.2%Short Interest in Adagio Therapeutics, Inc. (NASDAQ:ADGI) Drops By 13.2%...August 31, 2022 | marketbeat.comHedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%August 22, 2022 | 247wallst.comAdagio Therapeutics (NASDAQ:ADGI) Shares Gap Up on Insider Buying ActivityAugust 22, 2022 | marketbeat.comMarc Elia Buys 584,451 Shares of Adagio Therapeutics, Inc. (NASDAQ:ADGI) StockAugust 19, 2022 | marketbeat.comQ3 2022 EPS Estimates for Adagio Therapeutics, Inc. (NASDAQ:ADGI) Decreased by Jefferies Financial GroupAugust 18, 2022 | marketbeat.comAdagio Therapeutics GAAP EPS of -$0.47August 17, 2022 | seekingalpha.comAdagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsAugust 15, 2022 | finance.yahoo.comAdagio Therapeutics, Inc. (NASDAQ:ADGI) Short Interest Up 7.9% in JulyAugust 15, 2022 | marketbeat.comIs Adagio Therapeutics (NASDAQ:ADGI) In A Good Position To Invest In Growth?July 6, 2022 | finance.yahoo.comAdagio Elevates Interim Chief Executive David Hering To Permanent CEOJuly 5, 2022 | nasdaq.comMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignJuly 5, 2022 | finance.yahoo.comAdagio Announces David Hering Named Permanent Chief Executive Officer and DirectorJuly 5, 2022 | finance.yahoo.com(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact Johnson FistelJuly 2, 2022 | benzinga.comAdagio Therapeutics (NASDAQ:ADGI) PT Lowered to $3.00 at Morgan StanleyMay 17, 2022 | marketbeat.comAdagio Therapeutics Reports Q1 Net Loss of $100.7M, Cash Position of $532.2MMay 13, 2022 | investing.comAdagio Therapeutics Reports First Quarter 2022 Financial ResultsMay 13, 2022 | finance.yahoo.comAdagio stock falls after pausing filing plans for COVID therapy with FDAApril 14, 2022 | seekingalpha.comAdagio Therapeutics Provides Update on Timing of Adintrevimab EUA RequestApril 14, 2022 | finance.yahoo.comWhen Will Adagio Therapeutics, Inc. (NASDAQ:ADGI) Breakeven?April 7, 2022 | finance.yahoo.comThe Petri Dish: Adagio says its antibody works against omicron nowMarch 31, 2022 | bizjournals.comPeering Into Adagio Therapeutics Inc. - Common Stock's Recent Short InterestMarch 30, 2022 | msn.comThiel-backed venture firm Mithril seeks to nominate candidates for Adagio's boardMarch 30, 2022 | nasdaq.comMid-Afternoon Market Update: Dow Drops 100 Points; Adagio Therapeutics Shares Spike HigherMarch 30, 2022 | markets.businessinsider.comAdagio's stock jumps as company says it will seek authorization for COVID-19 antibody treatmentMarch 30, 2022 | finance.yahoo.comAdagio Stock Spikes on New Data, but Its Omicron Problems RemainMarch 30, 2022 | finance.yahoo.comWHO urges countries to keep up COVID-19 testing and surveillance as the viral outbreak remains a global pandemicMarch 30, 2022 | finance.yahoo.comWhy Adagio Therapeutics Stock Is Soaring TodayMarch 30, 2022 | finance.yahoo.comWhy Is Adagio Therapeutics (ADGI) Stock Up Today?March 30, 2022 | investorplace.comAdagio stock soars 78% as COVID drug ADG20 meets main goals in trial; EUA filing in Q2March 30, 2022 | seekingalpha.comAdagio Therapeutics Says Its Investigational Drug For Covid-19 Met Primary EndpointsMarch 30, 2022 | nasdaq.comAdagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use AuthorizationMarch 30, 2022 | finance.yahoo.comAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer | MorningstarFebruary 25, 2022 | morningstar.comMAdagio Therapeutics names David Hering as interim CEOFebruary 24, 2022 | seekingalpha.comAdagio Therapeutics Announces David Hering Appointed Interim Chief Executive OfficerFebruary 24, 2022 | finance.yahoo.comAdagio falls after announcing resignation of CEOFebruary 22, 2022 | seekingalpha.comAdagio Therapeutics Announces ADG20 Development Plans and Pipeline UpdatesFebruary 22, 2022 | finance.yahoo.comAdagio CEO Gerngross to exit Covid antibody company he foundedFebruary 22, 2022 | finance.yahoo.com Get Adagio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADGI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADGI Media Mentions By Week ADGI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADGI News Sentiment▼0.001.11▲Average Medical News Sentiment ADGI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADGI Articles This Week▼00▲ADGI Articles Average Week Get the Latest News and Ratings for ADGI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Adagio Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Prime Medicine News Today Inhibikase Therapeutics News Today Protalix BioTherapeutics News Today ZIVO Bioscience News Today CEL-SCI News Today Invizyne Technologies News Today Cortexyme News Today AlloVir News Today NKGen Biotech News Today Calidi Biotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADGI) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADGI Stock Alerts